Sudeep Pharma has reported a 15% increase in Q4 revenue for FY26, reaching ₹182 Cr, driven by steady margins and growing demand. The stock is currently trading at ₹678, indicating robust financials with a high PE ratio of 44.7, ROCE of 28.1%, and ROE of 25.2%.

Sudeep Pharma reported a significant 39% year-over-year growth in Q4 EBITDA, reaching ₹626M. The impressive performance led to an increased EBITDA margin of 34.3%, marking a notable improvement from the previous year's 28.6%.

Sudeep Pharma aims to double its production capacity to 86,200 MT by fiscal year 2027. This includes a greenfield project of 51,200 MT and an expansion in battery materials (iron phosphate) at 25,000 MT, while maintaining the existing specialty ingredients output at 37,500 MT. The move demonstrates a growing focus on battery materials.

Sudeep Pharma Ltd has announced a dividend of ₹1.50 per share following the release of their FY26 results, with auditors appointed for the upcoming year and a five-year audit term set through FY31.

Sudeep Pharma has reported a 28% increase in revenue for FY26, reaching Rs. 642.3 crore, along with a 26% growth in profits. The company has also acquired an 85% stake in Nutrition Supplies Services and is building a battery materials plant at Dahej.

Sudeep Pharma will announce their FY26 results and potential dividends during the board meeting on May 21, 2026. Trading is suspended until May 23 as they review their Q4 financials and consider a possible payout to shareholders.